Mollie Jurewicz
Director TScan Therapeutics
Seminars
Wednesday 20th May 2026
Expanding Treatable Patient Populations with a Novel CD45 Target
11:30 am
- Understanding the impact that broader patient impact will have on the haem space
- Outlining the lead selection process to identify a target restricted to the hematopoietic system, ensuring safe and efficacious therapies
- Presenting preclinical data from the TCR discovery process
